Italiano
EnglishFor over 50 years we have developed and marketed high quality tests capable of providing a speedy response to the needs of labs throughout the world.
What we do
We are a robust and reliable company operating in the field of biotechnologies, within which we develop, produce and market tests for diagnosing changes to the patient’s health, following infection, hormonal changes or cancer.
We are committed to improving the quality of life of people via preventive identification of potential clinical diseases using a broad range of products of the highest quality.
Technologies
OUR OFFER
Our offer includes both high routine and specialty tests in a wide range of clinical areas.
44 ME TOO TESTS
Main characteristics
- No R&D investments
- Low menu differentiation
- Very low marketing and R&D costs
42 HIGH VOLUME SPECIALTIES
Main characteristics
- Low R&D investments
- Menu differentiation
- Low marketing and R&D costs
32 DIFFERENTIATING SPECIALTIES
Main characteristics
- Significant R&D investments
- High menu differentiation
- Significant marketing and R&D costs
OUR TECHNOLOGICAL PLATFORMS
OUR CUSTOMERS
We serve all laboratories, offering fully automated solutions.
- Big sized labs
- Medium sized labs and hospital labs
- Small sized labs and POLs (Physician Office Labs)
OUR OFFER
Our offer includes diagnostic tests and Analyte Specific Reagents.
OUR TECHNOLOGICAL PLATFORMS
The LIAISON® MDX is an innovative thermocycler based on PCR technology (Polymerase Chain Reaction) with two disc options: the 8-well Direct Amplification Disc and the 96-well Universal Disc.
OUR CUSTOMERS
We serve all laboratories, offering fully automated solutions.
- Big sized labs
- Medium sized labs and hospital labs
- Small sized labs and POLs (Physician Office Labs)
Where we are
DiaSorin’s global presence is steadily growing.
To date, the Group headed by DiaSorin S.p.A. consists of 24 companies and 5 foreign branches, with offices across 5 continents and manufacturing premises producing its tests in 7 sites around the world.
DiaSorin markets its own tests and platforms worldwide through its commercial subsidiaries in Europe, United States, Mexico, Brazil, China, Australia and Israel. In other countries, the Group operates through an international network of over 200 independent distributors.
1H 2019
FY 2017
PRESENCE
188.1 €/MLN
28.1% OF SALES
+0.8%
"}, {"id":"usa","title":"USA","content":"+0.7%
"}, {"id":"messico","title":"MEXICO","content":"+9.6%
"}, {"id":"america-latina","title":"LATIN AMERICA","content":"42.2 €/MLN
6.3% OF SALES
-2.2%
"}, {"id":"brasile","title":"BRAZIL","content":"-6.2%
"}, {"id":"francia","title":"FRANCE","content":"+12.0%
"}, {"id":"germania","title":"GERMANY","content":"+16.5%
"}, {"id":"italia","title":"ITALY","content":"+12.2%
"}, {"id":"australia","title":"AUSTRALIA","content":"+17.4%
"}, {"id":"cina","title":"CHINA","content":"+5.8%
"}, {"id":"asia-pacifico","title":"ASIA PACIFIC","content":"129.4 €/MLN
19.3% OF SALES
+13.5%
"}, {"id":"europa-africa","title":"EUROPE & AFRICA","content":"309.5 €/MLN
46.3% OF SALES
+11.7%
"} ]101.2 €/MLN
28.9% OF SALES
+1.6%
"}, {"id":"usa","title":"USA","content":"+3.3%
"}, {"id":"messico","title":"MEXICO","content":"+11.0%
"}, {"id":"america-latina","title":"LATIN AMERICA","content":"20.0 €/MLN
5.7% OF SALES
-5.2%
"}, {"id":"brasile","title":"BRAZIL","content":"-8.2%
"}, {"id":"francia","title":"FRANCE","content":"-3.3%
"}, {"id":"germania","title":"GERMANY","content":"+0.7%
"}, {"id":"italia","title":"ITALY","content":"+21.6%
"}, {"id":"australia","title":"AUSTRALIA","content":"+10.7%
"}, {"id":"cina","title":"CHINA","content":"+10.7%
"}, {"id":"asia-pacifico","title":"ASIA PACIFIC","content":"64.7 €/MLN
18.5% OF SALES
+6.3%
"}, {"id":"europa-africa","title":"EUROPE & AFRICA","content":"164.3 €/MLN
46.9% OF SALES
+5.1%
"} ]
